Salvage chemotherapy with cladribine in a patient with recurrent malignant oligodendroglioma.
Oligodendrogliomas appear to be the most chemoresponsive subtype of gliomas. PCV (procarbazine, CCNU, vincristine) chemotherapy produces significant response rates and probable prolongation of survival. Unfortunately there is no well-defined second line chemotherapy. There is evidence that the purine analogue cladribine has activity in astrocytomas, which are much less sensitive to chemotherapy than oligodendrogliomas, but the use of cladribine in oligodendrogliomas has never been reported. We describe the unsuccessful use of cladribine as third line chemotherapy in a young man with an aggressive oligodendroglioma. The literature pertaining to chemotherapy for oligodendrogliomas is reviewed.